-
Novo Nordisk Provides Update on ZEUS Phase 3 Trial for Ziltivekimab
A New Approach to Cardiovascular Risk Novo Nordisk recently released an update regarding the ZEUS Phase 3 clinical trial, which is investigating the efficacy of ziltivekimab. This trial focuses on patients suffering from both atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), a population with significant unmet medical needs. Understanding the ZEUS Trial The…
-
A New Hope for Cardiovascular Health: Silence Therapeutics Reveals Positive Results for Divesiran
NASDAQ: $SLN A Breakthrough in Gene Silencing In a significant development for cardiovascular medicine, Silence Therapeutics has officially announced positive topline results from their Phase 2 SANRECO clinical trial. The study evaluated divesiran, an innovative investigational treatment designed to address high levels of lipoprotein(a) [Lp(a)]—a known genetic risk factor for cardiovascular disease. Understanding the SANRECO…